BIOLASE Announces Results of Annual Meeting

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it held its Annual Meeting of Stockholders on Monday, April 27 at the Company's corporate headquarters in Irvine, California, as scheduled. A quorum representing 88 percent of stockholders entitled to vote was present at the meeting in person or by proxy, and all proposals submitted were approved.

Stockholders elected all five of the Company's recommended director nominees – Paul N. Clark, Jonathan T. Lord, M.D., Frederic H. Moll, M.D., Jeffery M. Nugent and James R. Talevich – each of whom received "For" votes from more than 98 percent of the shares voted. Messrs. Clark, Nugent and Talevich and Drs. Lord and Moll were recommended by all three proxy advisory firms: ISS, Glass Lewis and Egan Jones.

Former Chairman and CEO Federico Pignatelli, who was on the ballot as a director nominee per a June 2013 agreement with the Company but announced on April 22 that he was withdrawing as a candidate for election to the Board, received "For" votes from less than 1 percent of the shares voted. Prior to his withdrawal, Mr. Pignatelli was not recommended by any of the three proxy advisory firms and had received less than 1 percent of the shares voted as of the date of his withdrawal.

BIOLASE stockholders also ratified a recent bylaw amendment that shifts litigation expenses to the unsuccessful party only if that party is a current or former director or acting on behalf of a current or former director. The amendment was designed to protect the Company from frivolous and expensive litigation that diverts money away from investment in the business and the future growth of BIOLASE.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, and markets innovative lasers in dentistry and medicine and also markets and distributes high-end 2D and 3D digital imaging equipment, CAD/CAM intraoral scanners, and in-office milling machines and 3D printers. BIOLASE’s products are focused on technologies that advance the practice of dentistry and medicine and offer benefits and value to healthcare professionals and their patients. The Company's proprietary laser products incorporate approximately 250 patented and 100 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. Its innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 27,600 laser systems. Laser products under development address the Company’s core dental market and other adjacent medical and consumer markets.

For updates and information on WaterLase and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, Pinterest at www.pinterest.com/biolase, LinkedIn at www.linkedin.com/company/biolase, Google+ at www.google.com/+BIOLASEIrvine, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and WaterLase® are registered trademarks of BIOLASE, Inc.

Sard Verbinnen & Co
Daniel Goldstein / Steven Goldberg
310-201-2040

Source: BIOLASE, Inc.

You May Also Be Interested In

• Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
• InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 26
• Vantage Drilling International Ltd. Schedules First Quarter 2024 Earnings Release Date and Conference Call